{"entity":{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","aka":["Hanmi Pharm","한미약품","KRX:128940"],"tldr":"Hanmi Pharmaceutical is one of South Korea's largest drug companies, known for its long-acting protein platform and for olmutinib, the third-generation EGFR inhibitor approved in Korea as Olita in 2016.","summary":"Hanmi Pharmaceutical, founded in 1973 and based in Seoul, is a research-driven South Korean pharmaceutical company. Its LAPSCOVERY platform produced efpeglenatide and the neutropenia drug eflapegrastim (Rolvedon), and it has out-licensed several oncology candidates including the pan-RAF inhibitor belvarafenib and the FLT3 inhibitor tuspetinib. Olmutinib (HM61713), a third-generation EGFR T790M inhibitor, received conditional approval in Korea in 2016; Boehringer Ingelheim returned its licence the same year after cases of severe skin toxicity.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.hanmipharm.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["olmutinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"pharma","website":"https://www.hanmipharm.com/","ticker":"KRX:128940","founded":1973,"stage":"public","investors":[],"funding":[]},"route":"/companies/hanmi-pharmaceutical/","neighbours":{"drug":[{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/"}]}}